Hye Jin Chung

Hye Jin Chung

Auto-generated profile, based on publicly available information

Hye Jin Chung

Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JKJay H. Kalin
Jay H. Kalin
MWMuzhou Wu
Muzhou Wu
AGAndrea V. Gomez
Andrea V. Gomez
YSYun Song
Yun Song
JDJayanta Das
Jayanta Das
PCPhilip Cole
Philip Cole
Here we report corin, a synthetic hybrid agent derived from the class I HDAC inhibitor (entinostat) and an LSD1 inhibitor (tranylcypromine analog). Enzymologic analysis reveals that corin potently targets the CoREST complex and shows more sustained inhibition of CoREST complex HDAC activity compared with entinostat. Cell-based experiments demonstrate that corin exhibits a superior anti-proliferative profile against several melanoma lines and cutaneous squamous cell carcinoma lines compared to its parent monofunctional inhibitors but is less toxic to melanocytes and keratinocytes. CoREST knockdown, gene expression, and ChIP studies suggest that corin’s favorable pharmacologic effects may rely on an intact CoREST complex. Corin was also effective in slowing tumor growth in a melanoma mouse xenograft model. These studies highlight the promise of a new class of two-pronged hybrid agents that may show preferential targeting of particular epigenetic regulatory complexes and offer unique therapeutic opportunities.

1 January 2010 in Dermatologic Clinics
Verified
Journal Article
Closed access
HCHye Jin Chung
Hye Jin Chung
JUJouni J. Uitto
Jouni J. Uitto

17 February 2009 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
DKDae Hyun Kim
Dae Hyun Kim
HCHye Jin Chung
Hye Jin Chung
JBJoachim Bleys
Joachim Bleys
RGReza F. Ghohestani
Reza F. Ghohestani
High cost, poor compliance, and systemic toxicity have limited the use of pentavalent antimony compounds (SbV), the treatment of choice for cutaneous leishmaniasis (CL). Paromomycin (PR) has been developed as an alternative to SbV, but existing data are conflicting. We searched PubMed, Scopus, and Cochrane Central Register of Controlled Trials, without language restriction, through August 2007, to identify randomized controlled trials that compared the efficacy or safety between PR and placebo or SbV. Primary outcome was clinical cure, defined as complete healing, disappearance, or reepithelialization of all lesions. Data were extracted independently by two investigators, and pooled using a random-effects model. Fourteen trials including 1,221 patients were included. In placebo-controlled trials, topical PR appeared to have therapeutic activity against the old world and new world CL, with increased local reactions, when used with methylbenzethonium chloride (MBCL) compared to when used alone (risk ratio [RR] for clinical cure, 2.58 versus 1.01: RR for local reactions, 1.60 versus 1.07). In SbV-controlled trials, the efficacy of topical PR was not significantly different from that of intralesional SbV in the old world CL (RR, 0.70; 95% confidence interval, 0.26–1.89), whereas topical PR was inferior to parenteral SbV in treating the new world CL (0.67; 0.54–0.82). No significant difference in efficacy was found between parenteral PR and parenteral SbV in the new world CL (0.88; 0.56–1.38). Systemic side effects were fewer with topical or parenteral PR than parenteral SbV. Topical PR with MBCL could be a therapeutic alternative to SbV in selected cases of the old world CL. Development of new formulations with better efficacy and tolerability remains to be an area of future research. Millions of people worldwide are suffering from cutaneous leishmaniasis that is caused by parasites of the genus Leishmania. Although pentavalent antimony compounds are the treatment of choice, their use is limited by high cost, poor compliance, and systemic toxicity. Paromomycin was developed to overcome such limitations. However, there is no consensus on its efficacy. This meta-analysis assessed the efficacy and safety of paromomycin compared with placebo and pentavalent antimony compounds. Fourteen randomized controlled trials, including 1,221 patients, met our selection criteria. Topical paromomycin appeared to have therapeutic activity against the old world and new world cutaneous leishmaniasis, with increased local reactions, when combined with methylbenzethonium chloride. Topical paromomycin was not significantly different from intralesional pentavalent antimony compounds in treating the old world form, whereas it was inferior to parenteral pentavalent antimony compounds in treating the new world form. However, a similar efficacy was found between parenteral paromomycin and pentavalent antimony compounds in treating the new world form. Fewer systemic side effects were observed with topical and parenteral paromomycin than pentavalent antimony compounds. These results suggest that topical paromomycin with methylbenzethonium chloride could be a therapeutic alternative to pentavalent antimony compounds for selected cases of the old world cutaneous leishmaniasis.

11 February 2022 in Dermatologic Surgery
Verified
Journal Article
Closed access
SCStella X. Chen
Stella X. Chen
JCJudy Cheng
Judy Cheng
JWJacqueline Watchmaker
Jacqueline Watchmaker
JDJeffrey S. Md Dover
Jeffrey S. Md Dover
HCHye Jin Md Chung
Hye Jin Md Chung
BACKGROUND: Lasers and energy-based devices (EBD) are popular treatments for skin rejuvenation and resurfacing. Achieving desired outcomes and avoiding complications require understanding the effects of these devices at a histologic level. Currently, no comprehensive review summarizing the histologic effects of laser and energy-based treatments exists. OBJECTIVE: To describe how lasers and EBD alter skin histology and improve the overall understanding of these devices. MATERIALS AND METHODS: A PubMed search was conducted for studies with histologic analysis of fractional picosecond laser, fractional radiofrequency microneedling, nonablative lasers, and ablative lasers. RESULTS: Fractional picosecond lasers induce intraepidermal and/or dermal vacuoles from laser-induced optical breakdown. Fractional radiofrequency microneedling delivers thermal energy to the dermis while sparing the epidermis, making it safer for patients with darker skin phototypes. Fractional nonablative lasers induce conical zones of coagulation of the epidermis and upper dermis. Ablative lasers vaporize the stratum corneum down to the dermis. Traditional ablative lasers cause diffuse vaporization while fractional ablative lasers generate columns of tissue ablation. CONCLUSION: Lasers and EBD are effective for skin resurfacing and rejuvenation and have different mechanisms with disparate targets in the skin. Safe and effective use of devices requires understanding the histologic laser–tissue interaction.

1 August 2008 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
HIHiroki Inui
Hiroki Inui
KOKyu-Seon Oh
Kyu-Seon Oh
CNCarine Nadem
Carine Nadem
TUTakahiro Ueda
Takahiro Ueda
SKSikandar G. Khan
Sikandar G. Khan
KKKenneth H Kraemer
Kenneth H Kraemer

1 June 2016 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
NRNicholas A. Ross
Nicholas A. Ross
HCHye-Jin Chung
Hye-Jin Chung
QLQiaoli Li
Qiaoli Li
JAJonathan P. Andrews
Jonathan P. Andrews
MKMatthew S. Keller
Matthew S. Keller
JUJouni J. Uitto
Jouni J. Uitto
Pityriasis rubra pilaris (PRP) is an inflammatory papulosquamous skin disorder first reported by Tarral in 18351 and later fully characterized by Devergie in 1856.2 The clinical features of classic PRP affecting the skin and nails are detailed elsewhere.3-5 Histopathologic findings reveal psoriasiform dermatitis with irregular hyperkeratosis and alternating vertical and horizontal orthokeratosis and parakeratosis, referred to as the “checkerboard pattern.”6 Acantholysis and focal acantholytic dyskeratosis within the epidermis have been described, features which have been suggested to be helpful in distinguishing PRP from psoriasis.7